2-(2,2-diethyl[1,3]dioxolan-4-yl)ethanol | 149716-35-8

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 2-(2,2-diethyl[1,3]dioxolan-4-yl)ethanol
• 英文别名: 2-(2,2-Diethyl-1,3-dioxolan-4-yl)ethanol
• CAS: 149716-35-8
• 化学式: C₉H₁₈O₃
• 分子量: 174.24
• InChiKey: ZFLMDSXNYOCQST-UHFFFAOYSA-N

物化性质

• 沸点：
  240.8±15.0 °C(Predicted)
• 密度：
  0.970±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.2
• 重原子数：
  12
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  38.7
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  2-(2,2-diethyl[1,3]dioxolan-4-yl)ethanol 在 吡啶 、 四丁基氟化铵 、 sodium hydride 作用下， 以 四氢呋喃 、 N,N-二甲基甲酰胺 为溶剂， 生成 (2S,4S,5R,6R)-4-Acetoxy-5-acetylamino-6-[(S)-[2-(2,2-diethyl-[1,3]dioxolan-4-yl)-ethoxy]-((R)-2,2-dimethyl-[1,3]dioxolan-4-yl)-methyl]-2-methoxy-tetrahydro-pyran-2-carboxylic acid methyl ester
  参考文献：
  名称：

  Synthesis and anti-influenza evaluation of orally active bicyclic ether derivatives related to zanamivir

  摘要：

  We synthesized bicyclic ether sialidase inhibitors Such as tetrahydro-furan-2-yl. tetrahydro-pyran-2-yL and oxepan-2-yl derivatives related to zanamivir. These compounds substituted by diol at the C-3' and C-4' positions resulted in the retention of low nanomolar inhibitory activities against not only influenza A virus sialidase but also influenza A virus in cell culture. Compound I la in particular showed comparable efficacy in vivo relative to that of oseltamivir phosphate. (C) 2003 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0960-894x(02)01039-9
• 作为产物：
  描述：

  1,2,4-丁三醇 、 3-戊酮 在 molecular sieve 2-甲基苯磺酸 作用下， 以 四氢呋喃 、 乙酸乙酯 为溶剂， 生成 2-(2,2-diethyl[1,3]dioxolan-4-yl)ethanol
  参考文献：
  名称：

  Sulphur-containing amphiphilic agents for the transfer of biologically active molecules into cells

  摘要：

  本发明涉及两性、阳离子磺基取代的磷脂酰乙醇胺类似物及其盐，这些类似物能够与生物高聚物如DNA、RNA、寡核苷酸、核糖核酸酶、蛋白质和肽类结合，并将它们渗透到真核细胞中。特别适用的化合物是由1,2-二油酰-3-sn-磷脂酰乙醇胺（DOPE）衍生而来的，在这些化合物中，DOPE的磷酸酯基团被一个同分异构体基团CH2—SO—CH2或CH2—S(O)2—CH2所取代。由于它们与生物活性分子（如DNA或RNA）形成聚集物的特性，这些化合物特别适用于基因治疗的应用，同时也适用于诊断目的。

  公开号：

  US20050048108A1

文献信息

• A strategy of ketalization for the catalytic selective dehydration of biomass-based polyols over H-beta zeolite
  作者：Penghua Che、Fang Lu、Xiaoqin Si、Hong Ma、Xin Nie、Jie Xu

  DOI：10.1039/c7gc03248j

  日期：——

  site in sugar alcohols by the ketalization of the vicinal-diol group for the highly selective formation of tetrahydrofuran derivatives. A ketone firstly reacts with terminal vicinal hydroxyl groups to form the 1,3-dioxolane structure. This structure of the constrained 1,3-dioxolane ring would improve the accessibility of reactive groups to facilitate intramolecular etherification. As a better leaving

  与基于石油的化学物质相比，生物质包含大量的羟基，这些羟基可导致富氧结构。脱水是除氧最节能的技术。然而，糖醇中的多个相似的邻位羟基对其选择性脱水提出了重大挑战。在这里，我们提出了一种新的策略，可以通过邻位二醇基团的缩酮化来控制糖醇中的醚化位点，从而高度选择性地形成四氢呋喃衍生物。酮首先与末端邻位羟基反应形成1,3-二氧戊环结构。受限的1，3-二氧戊环环的这种结构将改善反应性基团的可及性，以促进分子内醚化。作为一个比水更好的离开群体，酮还可以促进分子内醚化。因此，在温和的反应条件下，使用H-β沸石催化剂可以以优异的收率生产出一系列四氢呋喃衍生物。该战略为有效提升生物质资源开辟了新的机遇通过羟基的修饰或保护。
• Novel Substituted Tetracyclic Tetrahydrofuran, Pyrrolidine and Tetrahydrothiophene Derivatives and Their Use as a Medicament
  申请人：Megens Antonius Adrianus Hendrikus Petrus

  公开号：US20090023721A1

  公开（公告）日：2009-01-22

  This invention concerns novel substituted tetracyclic tetrahydrofuran, pyrrolidine and tetrahydrothiophene derivatives with binding affinities towards serotonin receptors, in particular 5-HT 2A and 5-HT 2C receptors, and towards dopamine receptors, in particular dopamine D2 receptors and with norepinephrine reuptake inhibition properties, pharmaceutical compositions comprising the compounds according to the invention, the use thereof as a medicine, in particular for the prevention and/or treatment of a range of psychiatric and neurological disorders, in particular certain psychotic, cardiovascular and gastrokinetic disorders and processes for their production. The compounds according to the invention can be represented by general Formula (I) and comprises also the pharmaceutically acceptable acid or base addition salts thereof, the stereochemically isomeric forms thereof, the N-oxide form thereof and prodrugs thereof, wherein all substituents are defined as in Claim 1.

  这项发明涉及一种新的取代四环四氢呋喃、吡咯烷和四氢噻吩衍生物，其具有对5-HT2A和5-HT2C受体，特别是对多巴胺D2受体和去甲肾上腺再摄取抑制性能的结合亲和力，并且还包括根据本发明的化合物的制药组合物，其用作药物，特别是用于预防和/或治疗一系列精神和神经疾病，特别是某些精神病、心血管和胃动力障碍，以及其制备方法。根据本发明的化合物可以用一般式（I）表示，并包括其药学上可接受的酸或碱盐，其立体化学异构体形式，其N-氧化物形式和其前药，其中所有取代基在权利要求1中定义。
• NOVEL SUBSTITUTED TETRACYCLIC TETRAHYDROFURAN, PYRROLIDINE AND TETRAHYDROTHIOPHENE DERIVATIVES
  申请人：CID-NÚÑEZ José Maria

  公开号：US20100331325A1

  公开（公告）日：2010-12-30

  This invention concerns novel substituted tetracyclic tetrahydrofuran, pyrrolidine and tetrahydrothiophene derivatives with binding affinities towards serotonin receptors, in particular 5-HT 2A and 5-HT 2C receptors, and towards dopamine receptors, in particular dopamine D2 receptors and with norepinephrine reuptake inhibition properties, pharmaceutical compositions comprising the compounds according to the invention, the use thereof as a medicine, in particular for the prevention and/or treatment of a range of psychiatric and neurological disorders, in particular certain psychotic, cardiovascular and gastrokinetic disorders and processes for their production. The compounds according to the invention can be represented by general Formula (I) and comprises also the pharmaceutically acceptable acid or base addition salts thereof, the stereochemically isomeric forms thereof, the N-oxide form thereof and prodrugs thereof, wherein all substituents are defined as in Claim 1.

  本发明涉及一种新型取代四环四氢呋喃、吡咯烷和四氢噻吩衍生物，具有与血清素受体结合亲和力，特别是5-HT2A和5-HT2C受体，以及多巴胺受体，特别是多巴胺D2受体和去甲肾上腺再摄取抑制性能，制备了包括本发明化合物的药物组合物，其用途作为药物，特别是用于预防和/或治疗一系列精神和神经系统疾病，特别是某些精神病、心血管和胃动力障碍，以及它们的生产过程。本发明的化合物可以用通式（I）表示，并包括其药学上可接受的酸或碱盐，其立体化学异构体形式，其N-氧化物形式和其前药，其中所有取代基如权利要求1所定义。
• Optically active compound having a delta- valerolactone ring and liquid crystal composition containing same
  申请人：MITSUBISHI RAYON CO., LTD

  公开号：EP0467721B1

  公开（公告）日：1996-03-27
• Synthesis of topsentolides A2 and C2, and non-enzymatic conversion of the former to the latter
  作者：Ryo Towada、Shigefumi Kuwahara

  DOI：10.1016/j.tet.2014.04.040

  日期：2014.6

  The first total synthesis of the marine-derived cytotoxin topsentolide A(2), which eventually culminated in its stereochemical determination, was accomplished in 17 steps from a known chiral alcohol. An improved synthesis of its congener, topsentolide C-2, from a synthetic intermediate of topsentolide A(2) was also performed by utilizing the Yamaguchi lactonization to construct its nine-membered lactone ring. Treatment of epoxide ring-containing topsentolide Ay with HCl/MeOH brought about its quantitative conversion into topsentolide C-2. (C) 2014 Elsevier Ltd. All rights reserved.